$618.00 Million in Sales Expected for Nu Skin Enterprises, Inc. (NUS) This Quarter

Equities research analysts predict that Nu Skin Enterprises, Inc. (NYSE:NUS) will announce sales of $618.00 million for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Nu Skin Enterprises’ earnings. The lowest sales estimate is $610.87 million and the highest is $629.50 million. Nu Skin Enterprises reported sales of $616.22 million in the same quarter last year, which would suggest a positive year over year growth rate of 0.3%. The firm is expected to report its next earnings results after the market closes on Tuesday, April 30th.

On average, analysts expect that Nu Skin Enterprises will report full year sales of $2.77 billion for the current fiscal year, with estimates ranging from $2.76 billion to $2.78 billion. For the next year, analysts anticipate that the company will report sales of $2.89 billion, with estimates ranging from $2.86 billion to $2.91 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Nu Skin Enterprises.

Nu Skin Enterprises (NYSE:NUS) last posted its earnings results on Wednesday, February 13th. The company reported $1.05 EPS for the quarter, meeting analysts’ consensus estimates of $1.05. The firm had revenue of $683.29 million during the quarter, compared to the consensus estimate of $676.76 million. Nu Skin Enterprises had a return on equity of 25.98% and a net margin of 4.55%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.20 EPS.

NUS has been the subject of a number of research reports. Zacks Investment Research downgraded Nu Skin Enterprises from a “hold” rating to a “sell” rating in a research report on Thursday, December 20th. ValuEngine downgraded Nu Skin Enterprises from a “hold” rating to a “sell” rating in a research report on Wednesday, March 20th. Bank of America set a $65.00 price target on Nu Skin Enterprises and gave the stock a “sell” rating in a research report on Friday, March 1st. Pivotal Research restated a “buy” rating and issued a $85.00 price target on shares of Nu Skin Enterprises in a research report on Wednesday, March 13th. Finally, Stifel Nicolaus downgraded Nu Skin Enterprises from a “hold” rating to a “sell” rating and lowered their price target for the stock from $63.00 to $43.00 in a research report on Monday, March 25th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $75.25.

Institutional investors and hedge funds have recently modified their holdings of the stock. YorkBridge Wealth Partners LLC bought a new stake in shares of Nu Skin Enterprises during the fourth quarter worth $31,000. NumerixS Investment Technologies Inc bought a new stake in shares of Nu Skin Enterprises during the fourth quarter worth $108,000. Advisors Asset Management Inc. lifted its position in shares of Nu Skin Enterprises by 151.9% during the third quarter. Advisors Asset Management Inc. now owns 2,345 shares of the company’s stock worth $193,000 after purchasing an additional 1,414 shares during the last quarter. NINE MASTS CAPITAL Ltd bought a new stake in shares of Nu Skin Enterprises during the third quarter worth $206,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Nu Skin Enterprises during the third quarter worth $224,000. Institutional investors own 76.15% of the company’s stock.

NYSE NUS opened at $50.42 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.82 and a debt-to-equity ratio of 0.46. The company has a market cap of $2.79 billion, a PE ratio of 14.32, a PEG ratio of 1.22 and a beta of 0.65. Nu Skin Enterprises has a one year low of $44.36 and a one year high of $88.68.

About Nu Skin Enterprises

Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic and personal care products.

Featured Story: Depreciation

Get a free copy of the Zacks research report on Nu Skin Enterprises (NUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nu Skin Enterprises (NYSE:NUS)

Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.